INTRODUCTION
I have been interested in the diagnosis and treatment of neutropenia for nearly 50 years, from when we had just a few antibiotic choices for managing febrile neutropenia to the present era with a huge array of testing strategies, worries about antibiotic resistance and options for growth factor treatments.
Several experts have recently recommended approaches to acute and chronic neutropenia in children and adults [1 && ,2 && , [3] [4] [5] [6] [7] [8] [9] and managing chemotherapy-induced neutropenia, including antibiotic therapy [10 && ,11,12,13 && ,14] . In this brief review, I suggest a stepwise clinical approach to diagnose and treat neutropenia.
CLINICAL APPROACH TO NEUTROPENIA
(1) Always get a complete medical history. The key questions are: (a) Is neutropenia part of an acute illness or was it found on routine examination? If it was found on routine examination and the patient is not ill, making the diagnosis can be deliberative. 
KEY POINTS
The study provides a stepwise approach to making the diagnosis in patients presenting with neutropenia.
Patients with fever and severe neutropenia should always have a careful examination and receive antibiotics as soon as possible.
Patients with severe chronic neutropenia benefit from treatment with granulocyte colony-stimulating factor (G-CSF); this review gives specific guidelines for treatment of these patients.
(b) The use of G-CSF to prevent and treat infections in patients with severe chronic neutropenia differs significantly from the use of this myeloid growth factor for prevention of infection in patients with chemotherapy-induced neutropenia. My recommendations are: (a) For chronic neutropenia, the minimal criteria for G-CSF are: absolute neutrophil count repeatedly less than 0.5 Â 10 9 /l with recurrent mouth ulcers and gum disease. The goal is to prevent pain and loss of permanent teeth. Recurrent fevers, cellulitis, abscesses, sinusitis, pneumonia, perirectal infections are stronger criteria for recommending long-term G-CSF treatment. (b) The use of G-CSF for preventing infections in idiopathic, cyclic, and congenital neutropenia is based on a randomized controlled trial [15] . Effective doses of G-CSF vary by diagnosis (expressed as mg/kg/day and given daily, alternate day, or three times per week): idiopathic: median 1.2; cyclic: median 2.4; congenital: median 7.3. Patients with SCN presenting with a serious infection should be administered both G-CSF and antibiotics immediately. (c) Patients should be advised that the acute adverse events associated with initiation of G-CSF are primarily bone pain, arthralgias, myalgias, and headache with onset a few hours after the injections [16] . There are less common adverse events including thrombocytopenia, skin rash, injection site reactions, vasculitis, and glomerulonephritis. Decreased bone density and osteoporosis are also reported but pathological fractures are uncommon [16] . The potential for increasing the risk of myeloid leukemia should also be discussed with each patient. Severe congenital neutropenia patients have a high risk of evolving to myelodysplastic syndrome and acute myeloid leukemia [17] . 
CONCLUSION
Neutropenia is no longer the challenge it once was to clinicians. The greatest challenge now is to provide truly useful 'point of care' information to clinicians, patients, and families when they need it.
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